Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Carboplatin
Drug ID BADD_D00364
Description Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982.[A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]
Indications and Usage Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma.[L32253] Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.[L32253]
Marketing Status approved
ATC Code L01XA02
DrugBank ID DB00958
KEGG ID D01363
MeSH ID D016190
PubChem ID 426756
TTD Drug ID D0X7HM
NDC Product Code 0703-4239; 55150-386; 63323-172; 68083-191; 63592-0271; 61703-339; 0703-4244; 0703-4246; 72659-863; 50742-447; 69448-005; 61703-600; 55150-334; 61703-262; 61703-360; 71288-100; 49812-0010; 16729-295; 55150-333; 61703-150; 68083-193; 68554-0084; 68083-190; 68083-192; 53104-7570; 54875-0002; 50742-448; 55150-335; 0703-4248
UNII BG3F62OND5
Synonyms Carboplatin | cis-Diammine(cyclobutanedicarboxylato)platinum II | CBDCA | Paraplatin | Paraplatine | Platinwas | Ribocarbo | Carboplat | Neocarbo | Carbosin | Carbotec | Ercar | JM-8 | JM 8 | JM8 | Nealorin | NSC-241240 | NSC 241240 | NSC241240 | Blastocarb
Chemical Information
Molecular Formula C6H12N2O4Pt
CAS Registry Number 41575-94-4
SMILES C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cyanosis24.03.01.007; 22.02.02.007; 23.06.04.005; 02.11.04.0040.001511%
Cystitis haemorrhagic20.03.02.0030.000112%Not Available
Deafness04.02.01.0010.001847%Not Available
Defaecation urgency07.02.04.0010.000336%Not Available
Dehydration14.05.05.0010.005440%
Dental caries07.09.01.0010.000168%
Depressed level of consciousness17.02.04.002--
Dermatitis23.03.04.0020.000168%Not Available
Dermatitis acneiform23.02.01.0040.000280%
Dermatitis allergic23.03.04.003; 10.01.03.0140.000448%Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.0040.000168%Not Available
Diarrhoea07.02.01.001--
Diarrhoea haemorrhagic07.02.01.002; 24.07.02.0040.000280%Not Available
Diplopia06.02.06.002; 17.17.01.0050.000392%Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.0150.000783%Not Available
Disseminated intravascular coagulation01.01.02.002; 24.01.01.0100.000336%
Disturbance in attention19.21.02.002; 17.03.03.001--
Diverticulum07.10.01.0010.000168%Not Available
Drug interaction08.06.03.001--Not Available
Dry mouth07.06.01.002--
Dysaesthesia23.03.03.077; 17.02.06.0030.000112%
Dysgeusia07.14.03.001; 17.02.07.003--
Dysphagia07.01.06.0030.003313%
Dyspnoea02.11.05.003; 22.02.01.0040.033623%
Dyspnoea at rest02.11.05.004; 22.02.01.0250.000448%Not Available
Dyspnoea exertional02.11.05.005; 22.02.01.0050.000470%Not Available
Dysuria20.02.02.0020.000560%
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.0010.000112%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 21 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene